FDA Investigator Nilufer M Tampal, PhD

Nilufer M Tampal, PhD has conducted inspections on 13 sites in 4 countries as of 28 Mar 2022. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
13
Last Inspection Date:
28 Mar 2022
Investigator Role:
FDA Investigation Participant
Redica ID:
100001590
Countries of Inspections:
United States of America, Canada, France, Germany
FDA Investigators that have inspected at least one site in common with Nilufer M Tampal, PhD:
Alan P Kurtzberg, Allen F Hall, Allen Lou, Arindam Dasgupta, PhD, Barbara J Maulfair, Barbara Janine Breithaupt, Barbara M Frazier, Bill Tacket, Jr, Bonita S Chester, Brunilda Torres, Carl J Montgomery, Carla A Norris, Carol S Sanchez, Charles M Edwards, Chris A Sack, Christina N Maurino, Christine M Whitby, CSO, Craig A Garmendia, Cynthia L Evitt, Dana M Klimavicz, Dawn L Wydner, Deborah B Nixon, Dr. Abhijit Raha, PhD, Dr. Sriram Subramaniam, PhD, Edwin Martinez, Eric C Nielsen, Eric M Mueller, PharmD, Eric S Weilage, George C Amedro, George Ivan Wey, Gianine E Tompkins, Iris C Macinnes, Jacqueline A O'shaughnessy, PhD, James M Kewley, James P Mcevoy, Jane E Nelson, Jeanne D Shaffer, Jeffrey P Raimondi, Jennifer A Longie Vollom, Jessica E Hensley, Jessica L Peterson, John A Kadavil, PhD, Jonathan R Campos, Jonee J Mearns, Joseph R Lambert, Jyoti B Patel, PhD, Kara A Scheibner, PhD, Karen M Kondas, Krystal O Ogunremi, Larry K Austin, Latonya M Mitchell, LCDR Ismael Olvera, IV, Linda R Kuchenthal, Lisa P Oakes, Lori A Gioia, Lynette P Salisbury, Margaret M Annes, Martin K Yau, PhD, Melkamu Getie Kebtie, PhD, Michael F Skelly, PhD, Mohsen Rajabi Abhari, FDA, Muralidhara B Gavini, PhD, Nancy A Bellamy, Pamela L Velez Vega, Patrick D Stone, MS, Patrick L Wisor, Peter R Lenahan, Raymond T Oji, Rebecca Rodriguez, Richard W Berning, Robert C Steyert, Rodney D Combs, Sarah Forney, Scott B Laufenberg, Sharon L Matson, Shirley H Isbill, Sripal R Mada, PhD, Stephanie L Shapley, Susan F Laska, MS, Susanna E Ford, Truong Xuan Nguyen (Andy), Vickie J Kanion, William L Bargo, Xikui Chen (nmi), PhD, Yiyue Zhang (nmi), PhD

Nilufer M Tampal, PhD's Documents

Publish Date Document Type Title
July, 2004 EIR IAL Biolytix - EIR, 2004-07-23
December, 2006 FDA 483 Response PAREXEL International GmbH - Form 483R, 2006-12-22
December, 2006 EIR PAREXEL International - EIR, 2006-12-01
October, 2002 FDA 483 Bioanalytical Systems Inc - Form 483, 2002-10-30
December, 2006 FDA 483 PAREXEL International - Form 483, 2006-12-01
October, 2002 FDA 483 Response Bioanalytical Systems Inc - Form 483R, 2002-11-08
February, 2005 FDA 483 Celerion, Inc - Form 483, 2005-02-15
October, 2004 FDA 483 MDS Pharma Services - Form 483, 2004-09-21
June, 2003 FDA 483 Biovail Contract Research - Form 483, 2003-06-13
September, 2005 FDA 483 Merck & Co., Inc. - Form 483, 2005-09-16
September, 2004 FDA 483 Response Neopharm Labs Inc - Form 483R, 2004-11-08
September, 2004 FDA 483 Neopharm Labs Inc - Form 483, 2004-09-30
December, 2006 EIR PAREXEL International GmbH - EIR, 2006-12-08
July, 2003 FDA 483 Response MDS Pharma Services - Form 483R, 2003-07-17
December, 2006 FDA 483 Response PAREXEL International - Form 483R, 2006-12-20
July, 2003 FDA 483 MDS Pharma Services - Form 483, 2003-07-17
April, 2007 EIR Altasciences Company Inc. - EIR, 2007-05-23
July, 2003 EIR Christian Aumais, M.D. - EIR, 2003-09-17
July, 2003 FDA 483 Response Christian Aumais, M.D. - Form 483R, 2003-07-14
July, 2003 FDA 483 Christian Aumais, M.D. - Form 483, 2003-07-10
April, 2003 EIR Celerion, Inc - EIR, 2003-04-25
October, 2004 EIR MDS Pharma Services - EIR, 2007-06-15
April, 2003 FDA 483 Celerion, Inc - Form 483, 2003-04-25
October, 2002 EIR Bioanalytical Systems Inc - EIR, 2002-10-30
September, 2004 EIR Neopharm Labs Inc - EIR, 2011-04-20
July, 2003 EIR MDS Pharma Services - EIR, 2003-09-24

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more